Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital

Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat

May 13, 2019 6:04 AM EDT

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of ($0.01), $0.12 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $1.6 million.

Total net revenue in the first quarter 2019 was $12.4 million.Selling, general and administrative expenses for the first quarter of 2019 totaled $8.4 million as compared to $2.7 million in the first quarter of 2018. The increase is primarily attributed to commercial launch expenses, as well as the patient services programs to support... More